DEC 0 9 2003

FAX TRANSMITTAL TO THE UNITED STATES PATENT OFFICE Applicants Docket Number: CERTIFICATE OF TRANSMISSION **DEAV2002/0045 US NP** I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450. Alexandria. Applicants: VA 22313-1450, at (703) 872-9306, on Stefanie Flohr, et al Date of Deposit Printed Name of Person Signing Certificate Maribel Mendez Serial No. 10/613,482 **Total Number of Pages Sent:** Filing Date: Attorney: **Balaram Gupta** July 3, 2003 Group Art Unit: 1614 Title of Invention: Examiner: Not Yet Assigned Pyrazoloisoquinoline Derivatives for Inhibiting NFkappaB-Inducing Kinase TO: Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc. Amendment, 37 CFR Fee Transmittal Charge deposit account, in duplicate Petition under 37 CFR Extension of Time Petition Other . Issue Fee Transmittal & Advance Order 冈 Other <u>Submission of Executed Power of</u>

Attorney.

Receipt Confirmed:

Signed Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

Maintenance Fee Transmittal

PATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Not Yet Assigned

DEC 0 9 2003

In re Application of Stefanie Flohr, et al

Art Unit:

1614

CENTRAL FAX CENTER

Application No.: 10/613,482

Filed:

July 3, 2003

Title:

Pyrazoloisoquinoline Derivatives For Inhibiting NFkappaB-Inducing Kinase CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner of Patents, P.O. Box 1450, Alexandria,

VA 22313-1450, 1600, at 703-872-9306, on Date of Deposit

Printed Name of Person Signing Certificate

SUBMISSION OF POWER OF ATTORNEY UNDER 37 C.F.R. 1.34

Mail Stop Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith the Power of Attorney for the present application.

The Commissioner is hereby authorized to charge any additional fees, which may be required by this, paper, or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Balaram Gupta, Reg. No. 40,009

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3364 Telefax (908) 231-2626

Docket No. DEAV2002/0045 US NP

Aventis Docket No. DEAV2002/0045 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stefanie Flohr, et al

Examiner:

Not Yet Assigned

Serial No.: 10/613,482

Group Art Unit.:

Not Yet Assigned

Filed:

July 3, 2003

Title:

Pyrazoloisoquinoline Derivatives For Inhibiting NFkappaB-Inducing Kinase

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dr. Elmar-Michael Wein and . Dr. Hans-Jürgen Fischer Signatories of Aventis Pharma Deutschland GmbH, Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date:

By:

By:

Title:

Prokurist

<u>Handlungsbevollmächtigter</u>

Date:

November 11, 2003

Date:

Title:

2003 November 11,

Address correspondence and telephone calls to: Balaram Gupta, Reg. No. 40,009 Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-3364

Telefax

(908) 231-2626